RESUMO
Cytokines, key contributors to tumorigenesis, are mediators between inflammatory immune or nonimmune and cancer cells. Here, IL-6 production by tumor cells was assessed in a cohort of patients with lung adenocarcinoma treated with conventional therapy. IL-6 levels and neutrophil-lymphocyte ratio (NLR) or systemic immune-inflammation index (SII) markers were evaluated. Changes in pro- and anti-inflammatory cytokines, HMGB1 concentration, and CD4+ and CD8+ T-lymphocyte populations and their subpopulations were investigated. IL-6 expression was detected immunohistochemically in lung adenocarcinoma biopsies. Cytokines were quantified using the cytometric bead array, and TGF-ß and HMGB-1 through ELISA. Clinical parameters were collected to assess NLR and SII. CD4+ and CD8+ T-lymphocytes and naïve, memory, and effector subpopulations were quantified by flow cytometry. The data obtained were associated with patients' median overall survival (OS). IL-6 showed the highest increase, probably because the lung adenocarcinoma cells produced IL-6. Patients with higher OS had lower NLR and SII from the third cycle of chemotherapy. Patients with lower OS had significantly lower percentages of CD8+ T-lymphocyte and its effector subpopulations, with a concomitant increase in the naïve subpopulation. This study suggests that in addition to the known inflammatory markers, IL-6, CD8+ T-lymphocytes and their effector and naïve subpopulations could be useful as predictive markers in lung adenocarcinoma.
RESUMO
La coinfección con los virus de hepatitis B (VHB) y/o hepatitis C (VHC) puede provocar complicaciones en el paciente VIH+. El objetivo de este estudio fue evaluar la frecuencia de marcadores serológicos en la coinfección del VHB y/o VHC en plasmas de pacientes infectados por VIH y su correlación con el estatus virológico del VIH e inmunológico del paciente. Se evaluaron 1.846 plasmas positivos para VIH, referidos al Instituto Nacional de Higiene Rafael Rangel para la determinación de marcadores serológicos del VHB y VHC. Se realizaron análisis de carga viral del VIH-1 y recuento de linfocitos T CD4+/CD8+ para evaluar el estatus virológico e inmunológico, respectivamente de la población estudiada. La frecuencia de coinfección por VHB ó VHC fue de 15% y 5%, respectivamente mientras que la coinfección VHB/VHC fue de 0,16% (3/1.846) en pacientes infectados por VIH. No se observó asociación entre presencia de marcadores serológicos del VHB ó el VHC y bajos ó elevados niveles de ARN genómico del VIH (p=0,81 y p=0,31, respectivamente) ni valores bajos ó normales del índice CD4/CD8 (p=0,75 y p=0,06, respectivamente). Estos resultados sugieren que la coinfección con VHB o VHC no parece influir en los estatus virológico e inmunológico de la población evaluada.
Co-infection with hepatitis B (HBV) virus and/or hepatitis C (HCV) virus can induce complications in HIV+ patients. The purpose of this study was to evaluate the frequency of serologic markers in HBV and/ or HCV in plasma of HIV infected patients, and its correlation with the HIV viral status and the immunological status of the patient. The study included the evaluation of 1,846 HIV positive plasmas referred to the Instituto Nacional de Higiene Rafael Rangel for the determination of HBV and HCV serologic markers. The evaluation of the viral and immunological status was done by the analysis of the HIV-1 viral load and CD4+/CD8+ T lymphocyte counts, respectively, in the population studied. The frequency of HBV or HCV co-infection was 15% and 5%, respectively, while HBV/HCV co-infection was 0.16% (3/1,846) in HIV infected patients. There was no association between the presence of HBV or HCV serologic markers and low or normal values of the HIV genomic RNA (p=0.81 and p=0.31, respectively) nor low or normal values of the CD4/CD8 index (p=0.75 and p=0.06, respectively). These results suggest that HBV or HCV co-infection does not seem to influence the viral and immunological status of the evaluated population.